In preclinical studies, a synthetic lethal interaction between KRAS mutation and CDK4 inhibition indicates a potential therapeutic application for CDK4 and 6 inhibitors in NSCLC (17). This evidence concerns the gene CDK4 and non-small cell lung carcinoma.